U.S. Senator Tammy Baldwin Statement on Congressional Hearing with Mylan CEO on EpiPen Price Hike

Senators Baldwin and McCain introduced a bipartisan reform to hold drug corporations accountable for aggressive price increases

WASHINGTON, D.C. – U.S. Senator Tammy Baldwin released the following statement today regarding the House Oversight and Government Reform Committee hearing with the CEO of Mylan on the dramatic price increase for EpiPens:

“It’s great that Congress has been asking questions and seeking answers about this outrageous price hike. Regarding Mylan, it’s clear that this is just one example of what has become an all too common industry practice of systematically increasing prescription drug prices.

“This is why I am fighting for my bipartisan reform to require transparency and accountability for drug corporations who are jacking up costs for families in need of affordable lifesaving treatments and straining our federal budget. American taxpayers and families deserve an explanation for these soaring prescription drug prices and my bill to require basic transparency from drug corporations will help hold them accountable to the American people.”

Senator Baldwin and Senator John McCain (R-AZ) introduced the FAIR Drug Pricing Act last week. The bipartisan reform takes the first step in addressing skyrocketing prescription drug prices by requiring accountability and transparency for pharmaceutical corporations that plan to increase drug prices. More information on the legislation is available here.